Aligos Therapeutics, Inc. (ALGS) Misses Q4 EPS by 3c

Aligos Therapeutics, Inc. (NASDAQ: ALGS) reported Q4 EPS of ($0.51), $0.03 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $3.54 million versus the consensus estimate of $1.72 million.

For earnings history and earnings-related data on Aligos Therapeutics, Inc. (ALGS) click here.

You May Also Be Interested In

• Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
• Ideal Power (IPWR) Tops Q2 EPS by 2c
• Azitra, Inc. (AZTR) Tops Q2 EPS by 54c